Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.

The fact that the US Food and Drug Administration has approved using Dupixent to treat COPD positions Regeneron to generate billions of dollars in annual sales. Dupixent has the potential to ...

"The COPD PRS captures only a small proportion of ... Northpond Laboratories, Regeneron, Sanofi, and Apogee. Labaki disclosed no relevant conflicts of interest. Source Reference: Zhang J, et ...

COPD, and obesity, while also rapidly advancing our Factor XI antibodies to multiple Phase 3 trials. These programs represent significant opportunities for Regeneron to address substantial unmet ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...